BeiGene heads for profit milestone after hemorrhaging cash
With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
Recent Articles
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK
ONC.US
688235.SHG
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US
6160.HK
688235.SHG
RECENT ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
